{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:17:41Z","timestamp":1794968261244,"version":"4.9.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024\\u201300397123"],"award-info":[{"award-number":["RS-2024\\u201300397123"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003715","name":"Korea Research Institute of Bioscience and Biotechnology","doi-asserted-by":"publisher","award":["KGM4572431"],"award-info":[{"award-number":["KGM4572431"]}],"id":[{"id":"10.13039\/501100003715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002461","name":"Chungbuk National University","doi-asserted-by":"publisher","award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"10.13039\/501100002461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118485","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:52:30Z","timestamp":1756810350000},"page":"118485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A consensus HA DNA vaccine targeting clade 2.3.4.4 H5Nx influenza viruses provides broad cross-clade protection in mice and ferrets"],"prefix":"10.1016","volume":"191","author":[{"given":"Chang-Ung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Suk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pureum","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Bok","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Woo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahn Young","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4934-4931","authenticated-orcid":false,"given":"Doo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2025.118485_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3201\/eid3007.240508","article-title":"Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus infection in domestic dairy cattle and cats, United States, 2024","volume":"30","author":"Burrough","year":"2024","journal-title":"Emerg. Infect. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118485_bib2","doi-asserted-by":"crossref","first-page":"e3255","DOI":"10.1111\/tbed.14551","article-title":"Emergence of clade 2.3.4.4b novel reassortant H5N1 high pathogenicity avian influenza virus in South Korea during late 2021","volume":"69","author":"Sagong","year":"2022","journal-title":"Transbound. Emerg. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118485_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/irv.12324","article-title":"World health Organization\/World organisation for animal HF, agriculture organization HEWG. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014","volume":"9","author":"Smith","year":"2015","journal-title":"Influenza Other Respir. Virus"},{"issue":"1","key":"10.1016\/j.biopha.2025.118485_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.118485_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000049","article-title":"Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets","volume":"6","author":"Khurana","year":"2009","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118485_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/1348-0421.12478","article-title":"Antigenic diversity of H5 highly pathogenic avian influenza viruses of clade 2.3.4.4 isolated in Asia","volume":"61","author":"Ohkawara","year":"2017","journal-title":"Microbiol Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118485_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075209","article-title":"Structural and antigenic variation among diverse clade 2 H5N1 viruses","volume":"8","author":"Shore","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.biopha.2025.118485_bib8","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1128\/JVI.00025-15","article-title":"Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia","volume":"89","author":"Swayne","year":"2015","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118485_bib9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s10875-011-9563-1","article-title":"Individual antibody and t cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus","volume":"31","author":"Air","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"23","key":"10.1016\/j.biopha.2025.118485_bib10","doi-asserted-by":"crossref","first-page":"11756","DOI":"10.1128\/JVI.01460-06","article-title":"Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines","volume":"80","author":"He","year":"2006","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118485_bib11","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1128\/JVI.72.7.5648-5653.1998","article-title":"Protective CD4+ and CD8+ t cells against influenza virus induced by vaccination with nucleoprotein DNA","volume":"72","author":"Ulmer","year":"1998","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118485_bib12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118485_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102716","article-title":"GX-188E DNA vaccine plus pembrolizumab in HPV 16- and\/or 18-positive recurrent or advance cervical cancer: a phase 2 trial","volume":"74","author":"Lim","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118485_bib14","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2025.118485_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A phase II, prospective, randomized, multicenter, Open-Label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.biopha.2025.118485_bib16","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.biopha.2025.118485_bib17","article-title":"Rapid acquisition of polymorphic virulence markers during adaptation of highly pathogenic avian influenza H5N8 virus in the mouse","volume":"7","author":"Choi","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118485_bib18","article-title":"Soluble spike DNA vaccine provides Long-Term protective immunity against SARS-CoV-2 in mice and nonhuman primates","volume":"9","author":"Seo","year":"2021","journal-title":"Vaccin. (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118485_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints12","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118485_bib20","doi-asserted-by":"crossref","DOI":"10.4110\/in.2021.21.e28","article-title":"A \"prime and deploy\" strategy for universal influenza vaccine targeting nucleoprotein induces Lung-Resident memory CD8 t cells","volume":"21","author":"Chung","year":"2021","journal-title":"Immune Netw."},{"key":"10.1016\/j.biopha.2025.118485_bib21","unstructured":"FDA US. Considerations for Plasmid DNA Vaccines for Infectious Disease Indications: Guidance for Industry. 2007."},{"issue":"2","key":"10.1016\/j.biopha.2025.118485_bib22","first-page":"165","article-title":"Guidelines for nucleic acid detection and analysis in hematological disorders","volume":"37","author":"Hassan","year":"2015","journal-title":"Malays. J. Pathol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118485_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009724","article-title":"A non-neutralizing antibody broadly protects against influenza virus infection by engaging effector cells","volume":"17","author":"Ko","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2025.118485_bib24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3389\/fimmu.2019.01677","article-title":"Protective antibodies against influenza proteins","volume":"10","author":"Padilla-Quirarte","year":"2019","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118485_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.20506\/rst.19.2.1230","article-title":"Highly pathogenic avian influenza","volume":"19","author":"Swayne","year":"2000","journal-title":"Rev. Sci. Tech."},{"issue":"1","key":"10.1016\/j.biopha.2025.118485_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2025.118485_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3389\/fimmu.2020.00513","article-title":"Virus-induced t cell-mediated heterologous immunity and vaccine development","volume":"11","author":"Balz","year":"2020","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118485_bib28","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.4049\/jimmunol.1300954","article-title":"Protective CD8 t cell-mediated immunity against influenza a virus infection following influenza virus-like particle vaccination","volume":"191","author":"Hemann","year":"2013","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.biopha.2025.118485_bib29","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1403684111","article-title":"IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ t cells for heterosubtypic protection","volume":"111","author":"Valkenburg","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2025.118485_bib30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3201\/eid2406.172114","article-title":"Ferrets as models for influenza virus transmission studies and pandemic risk assessments","volume":"24","author":"Belser","year":"2018","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118485_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajpath.2019.09.017","article-title":"A guide for the use of the ferret model for influenza virus infection","volume":"190","author":"Belser","year":"2020","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118485_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12050668","article-title":"Infection with seasonal H1N1 influenza results in comparable disease kinetics and host immune responses in ferrets and golden Syrian hamsters","volume":"12","author":"Paterson","year":"2023","journal-title":"Pathogens"},{"issue":"15","key":"10.1016\/j.biopha.2025.118485_bib33","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1128\/JVI.00512-11","article-title":"Comparative pathology in ferrets infected with H1N1 influenza a viruses isolated from different hosts","volume":"85","author":"Smith","year":"2011","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118485_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01101-23","article-title":"Clade 2.3.4.4 H5 chimeric cold-adapted attenuated influenza vaccines induced cross-reactive protection in mice and ferrets","volume":"97","author":"Sun","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2025.118485_bib35","unstructured":"In-Depth Analysis: Human Respiratory Disease Associated with Avian Influenza A(H5N6). \u3008https:\/\/www.canada.ca\/en\/public-health\/services\/surveillance\/human-emerging-respiratory-pathogens-bulletin\/2022\/january\/in-depth-analysis-avian-influenza-a-h5n6.html\u3009."},{"issue":"10","key":"10.1016\/j.biopha.2025.118485_bib36","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1038\/s41591-024-03189-y","article-title":"Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus","volume":"30","author":"Khurana","year":"2024","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118485_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2302106","article-title":"Identification of specific neutralizing antibodies for highly pathogenic avian influenza H5 2.3.4.4b clades to facilitate vaccine design and therapeutics","volume":"13","author":"Tuan Duong","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.biopha.2025.118485_bib38","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3389\/fmicb.2017.02469","article-title":"Green tea Catechin-Inactivated viral vaccine platform","volume":"8","author":"Lee","year":"2017","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/j.biopha.2025.118485_bib39","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1128\/JVI.00728-15","article-title":"Intercontinental spread of Asian-Origin H5N8 to North America through beringia by migratory birds","volume":"89","author":"Lee","year":"2015","journal-title":"J. Virol."},{"issue":"Pt 10","key":"10.1016\/j.biopha.2025.118485_bib40","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1099\/vir.0.044032-0","article-title":"Antigenic analysis of highly pathogenic avian influenza virus H5N1 sublineages co-circulating in Egypt","volume":"93","author":"Watanabe","year":"2012","journal-title":"J. Gen. Virol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118485_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/v15112249","article-title":"Key amino acid residues that determine the antigenic properties of highly pathogenic H5 influenza viruses bearing the clade 2.3.4.4 hemagglutinin gene","volume":"15","author":"Zhang","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118485_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ t cell-mediated immunity induced by infection and vaccination","volume":"119","author":"Jansen","year":"2019","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118485_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"38","key":"10.1016\/j.biopha.2025.118485_bib44","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1016\/j.vaccine.2023.07.050","article-title":"Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection","volume":"41","author":"Liu","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118485_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118485_bib46","doi-asserted-by":"crossref","first-page":"a007252","DOI":"10.1101\/cshperspect.a007252","article-title":"Vaccine design for CD8 t lymphocyte responses","volume":"1","author":"Koup","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"7","key":"10.1016\/j.biopha.2025.118485_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107120","article-title":"Comparison of DNA vaccines with AddaS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2","volume":"26","author":"Neeli","year":"2023","journal-title":"iScience"},{"issue":"7855","key":"10.1016\/j.biopha.2025.118485_bib48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118485_bib49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad b cell responses","volume":"20","author":"Kanekiyo","year":"2019","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118485_bib50","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118485_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039075","article-title":"Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118485_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.727455","article-title":"Synthetic SARS-CoV-2 Spike-Based DNA vaccine elicits robust and Long-Lasting Th1 humoral and cellular immunity in mice","volume":"12","author":"Alamri","year":"2021","journal-title":"Front Microbiol"},{"issue":"36","key":"10.1016\/j.biopha.2025.118485_bib53","doi-asserted-by":"crossref","first-page":"13538","DOI":"10.1073\/pnas.0806901105","article-title":"A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.biopha.2025.118485_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103328","article-title":"Synthetic vaccine affords full protection to mice against lethal challenge of influenza b virus of both genetic lineages","volume":"24","author":"Gravel","year":"2021","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.biopha.2025.118485_bib55","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/588431","article-title":"Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A\/Vietnam\/1203\/04 (H5N1) influenza virus","volume":"197","author":"Lalor","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"677","key":"10.1016\/j.biopha.2025.118485_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo3332","article-title":"Vaccination with S(pan), an antigen guided by SARS-CoV-2 s protein evolution, protects against challenge with viral variants in mice","volume":"15","author":"Zhao","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.biopha.2025.118485_bib57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ymthe.2022.12.017","article-title":"A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19","volume":"31","author":"Aurisicchio","year":"2023","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2025.118485_bib58","article-title":"Long term Follow-Up study of a randomized, Open-Label, uncontrolled, phase I\/II study to assess the safety and immunogenicity of intramuscular and intradermal doses of COVID-19 DNA vaccine (AG0302-COVID19)","volume":"11","author":"Nakagami","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118485_bib59","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2018.11.064","article-title":"Preclinical evaluation of the efficacy of an H5N8 vaccine candidate (IDCDC-RG43A) in mouse and ferret models for pandemic preparedness","volume":"37","author":"Jeong","year":"2019","journal-title":"Vaccine"},{"issue":"5772","key":"10.1016\/j.biopha.2025.118485_bib60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1125548","article-title":"H5N1 virus attachment to lower respiratory tract","volume":"312","author":"van Riel","year":"2006","journal-title":"Science"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:40Z","timestamp":1778544040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":60,"alternative-id":["S0753332225006791"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118485","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A consensus HA DNA vaccine targeting clade 2.3.4.4 H5Nx influenza viruses provides broad cross-clade protection in mice and ferrets","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118485"}}